Selective COX-1 inhibitor (IC50=9nM). Shows 700-fold more selectivity over COX-2 (IC50=6.3µM). Inhibits COX-1-derived platelet thromboxane B2, gastric PGE2, and dermal PGE2 production. Orally active in rat.
Product Details
Alternative Name: | 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole |
|
Formula: | C17H12N2OClF3 |
|
MW: | 352.7 |
|
CAS: | 188817-13-2 |
|
Purity: | ≥98% |
|
Appearance: | White to off-white crystalline solid. |
|
Solubility: | Soluble in 100% ethanol, DMSO or dimethyl formamide; sparingly soluble in aqueous buffers. |
|
Shipping: | Ambient Temperature |
|
Long Term Storage: | -20°C |
|
Use/Stability: | Stable for at least 2 years after receipt when stored at –20°C. |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo: W. Li, et al.; Int. J. Mol. Sci.
12, 668 (2011),
Abstract;
Full Text
Prostaglandin E2-prostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression: K. Soontrapa, et al.; PNAS U.S.A.
108, 6668 (2011),
Abstract;
Full Text
Pharmacological analysis of cyclooxygenase-1 in inflammation: C.J. Smith, et al.; PNAS
95, 13313 (1998),
Abstract;
Full Text
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic: J.L. Masferrer, et al.; PNAS
91, 3228 (1994),
Abstract;
Full Text